Verrica Pharmaceuticals (VRCA) Projected to Announce Quarterly Earnings on Thursday

Verrica Pharmaceuticals (NASDAQ:VRCA) is projected to announce its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to post earnings of ($0.4974) per share and revenue of $6.20 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Verrica Pharmaceuticals Stock Performance

Shares of VRCA opened at $3.59 on Tuesday. The company has a market capitalization of $61.68 million, a PE ratio of -2.15 and a beta of 1.69. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.45 and a quick ratio of 1.33. Verrica Pharmaceuticals has a one year low of $3.08 and a one year high of $9.82. The company’s fifty day moving average price is $4.20 and its 200 day moving average price is $5.49.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Lake Street Capital assumed coverage on Verrica Pharmaceuticals in a research report on Thursday, August 27th. They issued a “buy” rating and a $9.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research report on Tuesday, October 13th. Finally, Wall Street Zen downgraded Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Verrica Pharmaceuticals has a consensus rating of “Hold” and an average target price of $12.67.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a dermatology-focused biopharmaceutical company developing and commercializing therapies for skin diseases that have limited or inadequate treatment options. The company’s activities center on prescription products designed for use by dermatologists and other healthcare professionals.

Verrica’s lead commercial product is YCANTHE (cantharidin) topical solution, 0.7%, a prescription treatment approved by the U.S. Food and Drug Administration for molluscum contagiosum in adults and children two years of age and older.